ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer

A subset of non-small cell lung cancer (NSCLC), which does not have a druggable driver mutation, is treated with platinum-based cytotoxic chemotherapy, but it develops resistance triggered by DNA damage responses. Here, we investigated the effect of activation of STAT3 by cisplatin on anti-apoptotic...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Eun Young, Jung, Ji Ye, Kim, Arum, Chang, Yoon Soo, Kim, Se Kyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2017
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358954/
https://www.ncbi.nlm.nih.gov/pubmed/28319809
http://dx.doi.org/10.1016/j.neo.2017.02.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358954/
https://www.ncbi.nlm.nih.gov/pubmed/28319809
http://dx.doi.org/10.1016/j.neo.2017.02.008

Ejemplares similares